Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
91
resultados
Última actualización
14/03/2026 [07:07:00]
Resumen de: US20260069689A1
The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
Resumen de: US20260071235A1
Provided herein are methods for preparing and characterizing SARS-cov2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections, and immune disorders. Also provided are compositions and methods for generating immune calls expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARS-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.
Resumen de: US20260071190A1
There are SARS coronavirus 2 recombinant vectors derived from a GH clade SARS coronavirus 2 Korean isolate, which express distinct reporter genes, and the production method thereof. A full-length clone of a SARS coronavirus 2 Korean isolate or a derivative thereof, according to one embodiment, can be used as a standard material for evaluating the efficacy of therapeutic agents and vaccines in cell lines and animal models while maintaining infectivity and replication capacity when restored to viruses, can be used to develop a large-scale testing method for therapeutic agent development, and can be used to develop attenuated vaccine strains. In addition, a SARS coronavirus 2 recombinant vector derived from a Korean isolate or a derivative thereof, expressing a reporter gene, can be used for high-capacity, rapid drug screening in the development of antibody therapeutic agents and antiviral agents.
Resumen de: US20260074014A1
Technology is disclosed for a method for screening genetic mutations that can be used to predict vaccine composition, the method may include selecting a plurality of genome samples, partitioning the plurality of genome samples into N groups, where N is an integer larger than 1, identifying genomic isolates with phenotypic statuses from each of the N groups of genome samples by training at least one linear support vector machine with the genome samples, the identification of the isolates between each of the N groups of the genomic isolates performed in parallel, and assessing the identified genomic isolates using a performance metric.
Resumen de: AU2026201333A1
The invention is directed to portions of proteins of gram-positive bacteria, gram-negative, acid-fast bacteria (Mycobacteria, Staphylococcus) and/or virus (SARS-COV-2, Influenza), and antibodies reactive against these portions that can be formulated as immunogenic compositions and vaccines for the treatment and prevention of a microbial and/or viral infections. Preferably, compositions of the invention contain one or more portions of selected microbial and/or viral proteins that, upon administration to a subject, generate an effective cellular and/or humoral immune response, modulate immunity and a cytokine response. Effective responses involve an increased generation of antibodies that enhance immunity against an infection and promote an enhanced a phagocytic response. Monoclonal antibodies produced against these peptides enhance phagocytosis and killing of bacteria, viruses, and other microbes by phagocytic cells, and enhance clearance from the blood. and enhance clearance from the blood. eb e b a n d e n h a n c e c l e a r a n c e f r o m t h e b l o o d
Resumen de: US20260069556A1
Methods for treatment and prevention of a viral infection in an animal, including a respiratory infection, like a coronavirus such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Influenza A such as H1N1, H3N2, H5N1, or respiratory syncytial virus. The compositions and methods include a therapeutically effective amount of about a 1% solution of N-chlorotaurine in water. The methods include administering N-chlorotaurine by eye drop to the eyes, nasal spray to the nostrils, by oral spray to the throat, by nebulizer to the lungs, and by cannula to the mammary glands.
Resumen de: US20260069675A1
A MERS-CoV vaccine with nucleic acid sequences having at least 90% identity to the spike gene of a MERS-CoV strain as a preventive measure against MERS-CoV infections is described. The nucleic acid sequences may include plasmid DNA (pDNA) or messenger RNA (mRNA) that are encapsulated by aluminosilicates. The aluminosilicates may be functionalized with aminopropyltrimethoxysilanes.
Resumen de: EP4707279A1
The present invention provides a compound useful for the treatment or prevention of SARS-CoV-2 novel coronavirus infection.The present invention relates to a compound represented by formula (I), its enantiomer, or a pharmaceutically acceptable salt thereof:whereinring A, R1 and R7, R2 and R4, X and Y, as well as Z are according to the definitions as described in the specification;use thereof for the treatment or prevention of SARS-CoV-2 novel coronavirus infection; and pharmaceutical compositions comprising the same.
Resumen de: AU2024263334A1
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Resumen de: WO2026047716A1
The present disclosure relates generally to receptor binding domain of SARS-CoV- 2 and nucleic acids encoding the receptor binding domain, wherein the receptor binding domain comprises one or more mutations at amino acid positions selected from the group comprising R28T, K38V or T, K126T, F138L, A157V, V165del, E166A or K or P, Q175E, S176P, A202G, or a combination thereof compared to SEQ ID NO: 1. Such a receptor binding domain can be included as one of the components or constituents of polypeptide or multisubunit peptide disclosed herein, including the nucleic acids encoding them.
Resumen de: WO2026047603A1
Disclosed herein are compositions comprising protein antigens and RNA encoding the same (eg., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can be used to address and/or overcome immune imprinting in SARS-CoV-2.
Resumen de: US20260061046A1
Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.
Resumen de: AU2024333842A1
The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the treatment or prophylaxis of a disease or infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2. In particular, the invention provides a vaccine composition comprising a polypeptide, wherein the polypeptide comprises one or more epitope sequences, wherein the one or more epitope sequences have the amino acid sequences of any one or more of the sequences of Table 1, or a variant thereof having at least 70% sequence identity thereto, and wherein the polypeptide sequence is no more than 1400 amino acids in length.
Resumen de: US20260053779A1
Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).
Resumen de: US20260053741A1
The invention relates to a product for treating viral diseases, such as COVID-19, via the nasal route. The product comprises a hydrogel based on water, glycerol and a carbomer.
Resumen de: WO2026040166A1
The present invention belongs to the technical field of bioinformatics, and relates to a machine-learning-based method for screening cross-differentially expressed genes between lung cancer and COVID-19 infection and correspondingly screening prognostic genes of lung cancer. The method comprises: acquiring cross-differentially expressed genes between lung cancer and COVID-19; screening the cross-differentially expressed genes between lung cancer and COVID-19 infection; using Cox regression and LASSO regression to correspondingly screen prognostic genes of lung cancer; and using a K-M survival analysis method, GO and KEGG enrichment analysis methods and a protein-protein interaction analysis method to analyze screened-out prognostic genes of lung cancer. The method provided herein can process data, and can also identify intricate patterns in the data, and has relatively high sensitivity and specificity, thereby improving the efficiency and accuracy of screening. The technique can be extended to the research of other diseases, and features universality.
Resumen de: US20260055061A1
Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to a subject with a traumatic brain injury, an inflammatory disorder, an autoimmune disorder, a neurodegenerative disease, a viral infection, or any combination thereof. The disclosed halophthalimides have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof,where R5 isAt least one of R2-R4 or Re is halo.
Resumen de: US20260053745A1
Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.
Resumen de: WO2024218171A1
Compounds of Formula (I), pharmaceutical compositions containing them and their use in the treatment of a SARS-CoV-2 infection.
Resumen de: US20260049994A1
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.
Resumen de: AU2024298416A1
The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent neutralizing activity against Coronavirus, in particular against at least one virus selected from SARS-CoV-2, SARS-CoV-1 and variants thereof. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Coronavirus, in particular SARS-CoV-2 and/or SARS-CoV-1 dependent diseases.
Resumen de: WO2026039749A1
Described herein are soluble HRC-based Hpopeptide inhibitors of coronaviruses identified using structure-guided design to incorporate charged or polar residues at specific sites in the peptide to enhance aqueous solubility. Also described are methods of treating a coronavirus infection using soluble HRC-based hpopeptide inhibitors.
Resumen de: US20260048058A1
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.
Resumen de: US20260049062A1
Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.
Nº publicación: US20260049367A1 19/02/2026
Solicitante:
ISTANBUL MEDIPOL UNIV [TR]
ISTANBUL MEDIPOL UNIVERSITESI
Resumen de: US20260049367A1
The present invention relates to a reaction mixture suitable for use in the diagnosis of Covid-19 by isothermal amplification method.
BOPI
Sede Electrónica
